NEW YORK, March 28, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of PTC Therapeutics, Inc. (“PTC” or the “Company”) (Nasdaq:PTCT) between May 7, 2014 and February 29, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the District of New Jersey. If you purchased or otherwise acquired PTC securities between May 7, 2014 and February 29, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/ptc-therapeutics.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects.
On February 23, 2016, PTC announced that it received a Refuse to File letter from the United States Food and Drug Administration (“FDA”) regarding the New Drug Application for Translarna. The FDA stated in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review. Then on February 29, 2016, the Company’s CEO acknowledged that, according to the FDA, the Company did not provide substantial scientific evidence of effectiveness as it eliminated “data from a majority of enrolled patients.”
If you suffered a loss in PTC you have until May 2, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/ptc-therapeutics.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips
Want to cut your energy bills? Here’s how five experts are doing it
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 



